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Abstract
Background: Hepatitis E virus (HEV) infection is considered to be of significant public health importance in many
developing countries. In this review, we aim to summarise studies on HEV with the aim of providing a further
understanding of the epidemiology of the disease in Ghana.
Methods: A systematic review was conducted by following the recommendations outlined in the PRISMA statement.
Studies on HEV infection among Ghanaians were identified by searching for articles (published up until 4th August
2016) in the PubMed, ISI Web of Science, African Journals Online, Google Scholar and the WHO African Index Medicus
databases. We also searched the websites of the Ministry of Health and the Ghana Health Service to identify any
related non-indexed studies. References of all retrieved studies were screened to identify additional publications.
Results: Ten studies involving a total of 2 894 participants from six regions of Ghana were identified. The proportion of
Ghanaians showing positive serological markers for HEV infection was within the range of 5.8–71.55%. In addition, 0.7–
45.9% tested positive for IgM antibodies while the proportion of Ghanaians testing positive for IgG antibodies was
within the range of 0–45.3%. One study reporting a case fatality rate of 66.7% among pregnant women was identified.
No information on HEV genotypes was retrieved.
Conclusions: Although based on a limited number of studies, this review does highlight that there is a high level of
HEV infection among Ghanaians. Preventive measures including educational interventions as well as general
improvements to sanitary and living conditions are needed to reduce the burden of the disease. Additionally, further
research regarding the contribution of the various HEV genotypes is urgently needed to fully understand the burden of
this disease in Ghana.
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Background
Types of viral hepatitis (A, B, C, D and E) that cause
acute and/or chronic infection and liver inflammation
are considered to be of significant global public health
importance [1]. Hepatitis E (HEV) infection has long
been regarded as being endemic in resource-poor re-
gions such as Africa and Southeast Asia, where frequent
outbreaks occur due to poor sanitation and hygiene [2,
3]. In more advanced countries, sporadic cases of acute
HEV have been traced to individuals with a past history
of travel to endemic areas [4]. According to the World
Health Organization (WHO), more than 20 million HEV
infections occur annually across the world resulting in
over 3 million symptomatic cases of hepatitis E [2].
Hepatitis E does not usually develop into a carrier state
and most individuals recover fully from acute HEV in-
fections [2, 5]. In a few instances, however, it may pro-
gress into fulminant hepatitis, with a case fatality rate of
around 1–2% in the general population [6] and as high
as 40% in pregnant women [7].
The 2010 Global Burden of Disease Study estimated
that there were more than 56 000 HEV-related deaths
annually [8]. Although, there is wide acceptance that
HEV is of significant public health importance in Ghana,
the burden of the disease has not been thoroughly* Correspondence: asensox215@gmail.com
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documented [9]. In this paper, we review studies on
HEV infection in Ghana to summarise the available evi-
dence regarding incidence and prevalence of the disease.
To our knowledge, this is the first systematic review that
has attempted to summarise the prevalence and inci-
dence of HEV infection in Ghana. This paper forms part
of an ongoing work aimed at documenting the burden
of common viral hepatitis in Ghana. Studies on the esti-
mated burdens of other hepatitis types arising from this
broad work have been published elsewhere [10, 11].
Methods
We conducted a systematic review of literature on HEV
infection by following the recommendations outlined in
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [12]. Studies report-
ing HEV infection among Ghanaians were identified by
searching for articles (published up to 4th August 2016) in
the PubMed, ISI Web of Science, Google Scholar, African
Journals Online and the WHO African Index Medicus
databases.
The keywords used were ‘Hepatitis E’ OR ‘Hepatitis E
virus’ OR ‘HEV’ OR ‘Hepatitis E antibody’* OR ‘non-A and
non-B (nAnB)’AND ‘epidemiology’ OR ‘prevalence’ OR ‘in-
cidence’AND ‘Ghana’. ‘Non-A’ and non-B (nAnB)’ were in-
cluded as search terms because HEV has been identified as
the causative agent in many epidemic and sporadic cases of
enterically transmitted non-A and non-B viral hepatitis in a
number of developing countries [13, 14]. We also searched
the websites of the Ministry of Health (http://www.moh-
ghana.org/) and the Ghana Health Service (http://www.gha-
nahealthservice.org/) to identify non-indexed studies and
policy reports on the subject.
In this review, we included serological studies that
reported on the detection of antibodies to HEV-
immunoglobulin G (IgG) or immunoglobulin M (IgM)
among Ghanaians. The detection of IgM was considered
to represent sporadic acute hepatitis cases [5, 15] and was
used to estimate the incidence of HEV infection. The de-
tection of IgG was considered to represent remote infec-
tion and was used to estimate HEV seroprevalence among
the population [15]. Studies assessing case fatality rate
were also included.
A 12-point scoring system, adapted from the Downs
and Black checklist [16], was used to assess the quality
of the individual studies. The scoring system included
questions such as whether study’s objective was clearly
defined, whether participant characteristics and whether
study’s conclusion was sound and based on the results.
Descriptive data such as the study population, year of
publication, region, setting and the proportion of people
who tested positive for IgG or IgM antibodies were sum-
marised. Due to the heterogeneity of the studies, a for-
mal meta-analysis was not conducted.
Results
Figure 1 summarises the steps used to retrieve the ap-
propriate studies. A total of 208 articles were retrieved.
After the titles and abstract were screened and dupli-
cates were removed, 13 studies were selected for full text
analysis. Out of these, 10 studies on HEV in Ghana were
selected for the review [9, 17–25].
The selected studies (see Table 1) included nine 9
serological studies that reported on the presence of
HEV antibodies and one study that focused on case
fatality rate. Taken together, the studies involved a
total sample population of 2 894 across six regions of
Ghana. The regional distribution of studies was as
follows: Ashanti (n = 3), Greater Accra (n = 6) and one
study that involved five regions (Ashanti, Brong-
Ahafo, Upper East, Upper West and Northern). The
majority of the studies (80%, n = 8) were conducted
solely among urban dwellers. Of the serological stud-
ies, one was conducted exclusively among children
[17], two studies were conducted among pig handlers
[18, 19], two among blood donors [20, 21], one in-
volved adult HIV patients [22], one involved pregnant
women [9], one involved persons with viral haemor-
rhagic fever symptoms [23] and one study involved
patients with suspected hepatitis [24]. The ten studies
were published between 1999 and 2016, however, the
sampling took place between 1993 and 2013. In terms
of the quality, 80% (n = 8) of the studies were deemed
as being of high quality and 20% (n = 2) were consid-
ered to be of medium quality.
Fig. 1 PRISMA flow chart showing the process of selecting studies
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Serological markers of HEV infection
Among the nine serological studies, the proportion of par-
ticipants testing positive for any HEV antibody (total Ig)
varied from 5.8% to 71.55%. The incidence of HEV infec-
tion as determined by the proportion of participants
across the seven studies showing positive results for IgM
was within the range of 0.7–45.9%. The highest incidence
of HEV as determined by IgM seropositivity was reported
for a cohort of blood donors (45.9%) [20] and pig handlers
(38.1%) [18]. The only study conducted among HIV
patients, however, reported a very low incidence rate, with
the proportion of participants testing positive for IgM
at 0.7% [22]. The seroprevalence of HEV infection (as
determined by the proportion of individuals testing
positive for IgG) across the seven studies was within
the range of 0–45.3%. Seroprevalence of 0% was reported
in a cohort of pig handlers [18] and 45.3% in a cohort of
HIV-positive adults [22].
Case fatality rate
Only one study reporting case fatality was identified. It
reported a case fatality rate of 66.7% among pregnant
women [25]. However, the study involved a small sample
size of only three cases.
Discussion
To our knowledge, this is the first systematic review that
has attempted to thoroughly summarise evidence on the
incidence and seroprevalence of HEV infection in Ghana.
Our results indicate that HEV infection in Ghana may be
quite high, with between 5.8% and 71.55% of Ghanaians
showing serological markers of past or current infection in
the studies under review. The discrepancies in the propor-
tion of Ghanaians testing positive for HEV serological
markers across the studies could be related to geographical
(regional) differences in the levels of HEV infection across
the country, as well as to the varied populations studied.
Table 1 Studies on hepatitis E in Ghana
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Ashanti 803 Rural Children 6-18 4.4 n.s n.s High








13-42 28.66 10.19 18.47 High








12–65 38.1 0.0 38.1 High
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Ashanti 239 Urban Blood
donors
n.s 10.5 4.6 5.9 High




Ashanti 402 Urban Adult HIV
patients





























33.0 ± 14.5 5.8 n.s n.s Medium

















31, 31, 17 66.7% High
VHF viral haemorrhagic fever; n.s not specified; m male; f female; IgG Immunoglobulin G; IgM immunoglobulin M; HEV RNA hepatitis E virus RNA
a median
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Almost 60% of the serological studies reported a
higher proportion of participants testing positive for
IgM than IgG. This by inference suggests that there is a
higher HEV incidence compared to prevalence among
Ghanaians, which may point to frequent outbreaks than
a usual or common situation (usually IgG is higher than
IgM). In HIV individuals, while the incidence (based on
IgM detection) appears to be very low, the prevalence
is very high. This may suggest that HEV infection in
HIV-positive Ghanaians persists for longer periods.
This longer persistence, which can sometimes lead to
chronic states, is also increasingly being reported glo-
bally [26, 27]. This trend is explained by the limited im-
mune system capacity of HIV patients to resolve acute
infections and HEV may be regarded as just another
form of opportunistic infection [27].
Only one study [9] was conducted among pregnant
women, which reported that 28.7% showed serological
markers of HEV infection. The highest proportion com-
prised women in the third trimester – an observation that
is consistent with globally reported trends [28]. HEV infec-
tion in pregnant women may pose additional health risks
due to the possible vertical transmission of the disease.
The two studies that focused on blood donors re-
ported that 10.5% and 71.55% tested positive for sero-
logical markers of HEV infection. While the clinical
relevance of transfusion-transmitted HEV remains un-
clear [29], studies have demonstrated the possibility of
HEV transmission through blood transfusions in en-
demic areas, following retrospective evaluations of trans-
fusion recipients [30]. As such, the high levels of HEV
infection among blood donors in Ghana could pose ser-
ious concerns regarding the safety of blood supply [31].
Although, Ghana has a mandatory policy that requires
the screening of all donated blood, this mainly covers
HIV 1 and 2, hepatitis B, hepatitis C and syphilis [32].
Therefore, attention must also be paid to HEV, as the
risk of spreading the virus through blood transfusion
could be high, as this review suggests.
The studies conducted among pig handlers reported
that over 38% showed serological markers of HEV infec-
tion. Adjei et al. [19] found that among pig handlers, the
risk of HEV infection correlated with the level of contact
with animals or their waste, and the absence of piped
water on the farms. Although the studies on pig han-
dlers in Ghana did not report on a particular genotype,
studies elsewhere have suggested possible zoonotic
transmission of HEV, especially of genotypes 3 and 4
[33, 34].
The study by Bonney et al. [25], although based on a
small sample size (n = 3), reported an HEV case fatality
rate of 66.7% among pregnant women in Ghana. This
rate is high when compared with the case fatality rate re-
ported in Sudan (31.1%) [35] and the Central African
Republic (14.3%) [36], although perhaps it is better to do
these comparisons when evidence of the HEV genotype
becomes available.
The seemingly high levels of HEV infection among
Ghanaians may be attributed to the low level of know-
ledge and awareness about the transmission pathways of
common viral hepatitis in the country [37, 38].
Additionally, many communities in Ghana are densely
populated and sanitation conditions remain precarious,
with only around 13% of Ghanaians estimated to have
access to improved sanitation [39]. All this may facilitate
the outbreak of HEV, particularly of genotypes 1 and 2
[2, 3, 9]. There is evidence of high faecal-oral transmis-
sion of HEV in African countries [40], which suggests
that public health measures may need to address issues
such inadequate access to safe water and poor sanitation
in an effort to control HEV outbreaks.
Currently, there is no specific treatment available for
HEV infection. However, a recombinant vaccine to
prevent the disease has been developed and recently ap-
proved in China, but is not yet available in any other
country [41]. Early studies on this vaccine have demon-
strated 95% efficacy in preventing HEV infection and
clinical disease [42, 43]. Once this vaccine becomes
widely available, it may be particularly useful for high-
risk groups such as HIV patients, in whom HEV infec-
tion remains high.
This study had some limitations. The main one is the
relatively small number of studies identified. This high-
lights that research and an understanding of the HEV in-
fection burden in Ghana is less developed compared to
research on and understanding of other viral infections.
The majority of the studies (80%, n = 8) involved samples
from only two regions of Ghana. Subsequently, no
samples from four regions (Central, Volta, Eastern and
Western) were included in the studies reviewed.
Additionally, there are four major genotypes of hepatitis
with different modes of transmission [44] and which
may require different approaches for control. The stud-
ies reviewed, however, did not report on these genotypes.
Furthermore, there are challenges in diagnosing HEV in-
fections and while there are many diagnostic assays, not
all have been rigorously tested and may at times present
incongruous results [45]. For instance, currently the US
Food and Drug Administration has not approved any
serologic test for HEV diagnosis [46].
Conclusions
Although this review is based on a limited number of
studies, it does highlight a high level of HEV infection
among Ghanaians. Preventive measures including educa-
tional interventions, screening of all donated blood and
high-risk groups (e.g., HIV patients), as well as general
improvement in sanitary and living conditions are
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needed to reduce the burden of the disease. Additionally,
further research regarding the contribution of the vari-
ous HEV genotypes is urgently needed to fully under-
stand the burden of the disease in Ghana.
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